Trial NCT05188677
Publication Rao C, medRxiv, 2022
Primary outcome on the report: 1) Demonstrate non-inferiority of a heterologous SCB-2019 boost compared with a homologous CoronaVac boost, when measured as neutralizing response against prototype Wuhan-Hu-1 SARS-CoV-2. 2) descriptive comparisons of incidence rates of solicited local reactions and systemic AEs through Day 7, unsolicited AEs up to Day 29, and SAEs and AESIs up to Day 60 in the two study groups.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.